Target intelligence / Profile preview

Purinergic receptor P2Y11 (P2Y11)

Target
P2Y11
Molecular classification
G protein-coupled receptor, Receptor, Purinergic receptor, Class A GPCR
01

Overview

Purinergic receptor P2Y11 is a member of the G protein-coupled receptor (GPCR) family, distinguished by its ability to respond to extracellular ATP (and possibly NAD+) and to couple to both phospholipase C (via Gq) and adenylyl cyclase (via Gs) signaling pathways—a unique feature among P2Y receptors[1][6][7][9]. P2Y11 plays critical roles in modulating immune responses, including regulation of cytokine production, cell migration (notably in T lymphocytes), and inflammation[3][4][5][7][9][10]. The receptor is expressed in a variety of immune cells such as dendritic cells, macrophages, and T cells, and redistribution of P2Y11 within migrating cells helps orchestrate polarization and efficient movement, particularly during immune responses[3][5]. Lack of rodent orthologs, limited antagonists, and complex signaling hamper its study, but P2Y11 is increasingly recognized as a modulator of inflammation, immune cell migration, and certain disease processes related to immune function and infection[1][4][9][10].

Other names
purinergic receptor P2Y, G-protein coupled, 11P2RY11P2Y purinoceptor 11
02

Mechanism of action

Agonists (e.g., ATP, possibly NAD+) activate P2Y11 to stimulate both phospholipase C (PLC) and adenylyl cyclase (AC) pathways, leading to increased intracellular calcium and cAMP; Antagonists (e.g., NF157) block these signaling pathways[1][6][9]

03

Biological functions

Signal transductionImmune responseCell migrationCytokine productionRegulation of mitochondrial metabolismInflammation
04

Disease associations

InflammationImmune disordersInfectionCancer (primarily as a regulator of immune response rather than a direct oncogene)Other (including sepsis and antiviral responses)
05

Safety considerations

Lack of selective pharmacological toolsreceptor is not present in rodents (hinders preclinical research)broad role in immune response could lead to immunosuppressive effects if chronically inhibitedrisk of impaired host defense in infection or cancer with inappropriate modulation[1][9][10]
06

Interacting drugs

NF157 (selective antagonist)[1][4][6]

3 more in the full profile.

07

Biomarkers

No established clinical biomarkers specific for P2Y11, but upregulation observed in certain activated immune cells such as M2 macrophages[9]possible relevance as an immune activation marker in research

Beyond the preview

Go deeper on Purinergic receptor P2Y11 (P2Y11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purinergic receptor P2Y11 (P2Y11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call